West Nile Virus News and Research

Latest West Nile Virus News and Research

Study on current insect repellants confirms need for better insect repellants

Fire up the citronella-scented tiki torches, and slather on the DEET: Everybody knows these simple precautions repel insects, notably mosquitoes, whose bites not only itch and irritate, but also transmit diseases such as West Nile virus, malaria and dengue. Now, Johns Hopkins scientists have discovered what it is in the bugs' molecular makeup that enables citronellal (the aromatic liquid used in lotions, sprays and candles) and DEET, to deter insects from landing and feeding on you. A better understanding of these molecular-behavioral links already is aiding the team's search for more effective repellants.

26 Aug 2010

Cerus to acquire BioOne's commercialization rights for INTERCEPT Blood System

Cerus Corporation announced today that it has signed an agreement to acquire BioOne Corporation's commercialization rights for the INTERCEPT Blood System for platelets and plasma, subject to approval of the transaction by BioOne's shareholders. In 2004 and 2005, Cerus and its partner at the time, Baxter International, licensed the commercialization rights for INTERCEPT platelets and plasma to BioOne for an Asian territory, which included China, Japan, Taiwan, Singapore, Korea, Thailand and Vietnam.

25 Aug 2010

Rush University Medical Center tests new drug therapy for West Nile fever

Neurological and infectious disease experts at Rush University Medical Center are testing a new drug therapy for the treatment of individuals with West Nile fever or suspected central nervous system infection due to the West Nile virus. Rush is the only site in the Midwest enrolling patients into the $50 million dollar, NIH-funded, Phase II clinical trial called PARADIGM.

18 Aug 2010

Human Immune Phenotyping Centers to receive NIAID grants for research

A new nationwide research initiative has been launched to define changes in the human immune system, using human and not animal studies, in response to infection or to vaccination. Six U. S.-based Human Immune Phenotyping Centers will receive a total of $100 million over five years to conduct this research.Funding for the centers is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Support for the first year of this initiative will come from the American Recovery and Reinvestment Act.

12 Aug 2010

Response Biomedical second-quarter revenue from product sales increases 2%

Response Biomedical Corporation today announced financial results for the second quarter and six months ended June 30, 2010.

10 Aug 2010

GG genotype may increase severity of multiple sclerosis symptoms: Study

A new study shows a gene variant may increase the severity of multiple sclerosis (MS) symptoms. The research will be published in the August 3, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.For the study, researchers screened the oligoadenylate synthetase gene in 401 people with MS, 394 people without MS and 178 people receiving the MS treatment beta interferon.

3 Aug 2010

Gen-Probe second-quarter 2010 product sales up 14%

Gen-Probe Incorporated today reported financial results for the second quarter of 2010, highlighted by 14% growth in product sales, 15% growth in total revenues, and 16% growth in non-GAAP earnings per share.

30 Jul 2010

Response Biomedical closes $8 million common share private placement

Response Biomedical Corporation announced today that it has closed its previously announced private placement of common shares for gross proceeds of approximately $8 million. The Company issued 13,333,333 common shares at a price of C$0.60 per share.

29 Jul 2010

Response Biomedical announces shareholder approval for $8 million private placement

Response Biomedical Corporation announced that at the Company's Special General Shareholders' Meeting held today in Vancouver, shareholders approved the private placement of an aggregate of 13,333,333 common shares, at a price of Cdn. $0.60 per Offered Share, to Caduceus Private Investments III, LP, OrbiMed Associates III, LP and Caduceus Asia Partners, LP for gross proceeds of approximately Cdn. $8 million.

28 Jul 2010

FDA can promote personalized medicine by identying gaps in laboratory operations: ACLA

The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.

17 Jul 2010

Pennsylvanians should take steps to reduce exposure to mosquitoes, Secretary of Health advises

The Pennsylvania Department of Health reminds Pennsylvanians to take precautions to reduce exposure to mosquitoes as the season arrives for West Nile virus, or WNV, infections.

15 Jul 2010

Sewage that overflows into urban creeks, streams can promote spread of West Nile virus: Study

Sewage that overflows into urban creeks and streams during periods of heavy rain can promote the spread of West Nile virus, a study led by Emory University finds. The analysis of six years of data showed that people living near creeks with sewage overflows in lower-income neighborhoods of Southeast Atlanta had a seven times higher risk for West Nile virus than the rest of the city.

13 Jul 2010

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has filed a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.

8 Jul 2010

Response Biomedical signs subscription agreement for C$8 million private placement

Response Biomedical Corporation announced today the signing of a subscription agreement providing for the sale of C$8 million of its common shares to funds affiliated with OrbiMed Advisors, LLC. The closing of the private placement is subject to receipt of all necessary regulatory approvals, including the approval of the Toronto Stock Exchange and the shareholders of the Company.

29 Jun 2010

Research could provide more effective treatment against West Nile virus

Protecting ourselves from backyard mosquito bites may come down to leaving the vacuuming for later, a study from York University shows.

29 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

Nihal Altan-Bonnet, assistant professor of cell biology, Rutgers University in Newark, and her research team have made a significant new discovery about RNA viruses and how they replicate themselves.

29 May 2010

FDA issues 510(k) clearance to Simplexa Influenza A H1N1 (2009) test on 3M Integrated Cycler

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration has issued 510(k) clearance to the Simplexa Influenza A H1N1 (2009) test on the 3M Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is the first to be cleared by the FDA for use as an aid in the detection and differentiation of influenza A and 2009 H1N1 influenza viral RNA.

25 May 2010

WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

The Whittemore Peterson Institute for Neuro-Immune Disease (WPI) and Cerus Corporation announced positive results from a study demonstrating the efficacy of the INTERCEPT Blood System to inactivate XMRV, a human retrovirus, in donated platelet components.

18 May 2010

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Response Biomedical Corporation today announced that it has been granted a Class 3 (near patient/point-of-care) Medical Device license by Health Canada to market its RAMP® Respiratory Syncytial Virus (RSV) Assay in Canada.

18 May 2010

West Nile Virus News and Research

Latest West Nile Virus News and Research

Study on current insect repellants confirms need for better insect repellants

Cerus to acquire BioOne's commercialization rights for INTERCEPT Blood System

Rush University Medical Center tests new drug therapy for West Nile fever

Human Immune Phenotyping Centers to receive NIAID grants for research

Response Biomedical second-quarter revenue from product sales increases 2%

GG genotype may increase severity of multiple sclerosis symptoms: Study

Gen-Probe second-quarter 2010 product sales up 14%

Response Biomedical closes $8 million common share private placement

Response Biomedical announces shareholder approval for $8 million private placement

FDA can promote personalized medicine by identying gaps in laboratory operations: ACLA

Pennsylvanians should take steps to reduce exposure to mosquitoes, Secretary of Health advises

Sewage that overflows into urban creeks, streams can promote spread of West Nile virus: Study

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Response Biomedical signs subscription agreement for C$8 million private placement

Research could provide more effective treatment against West Nile virus

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

FDA issues 510(k) clearance to Simplexa Influenza A H1N1 (2009) test on 3M Integrated Cycler

WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

West Nile Virus News and Research

Latest West Nile Virus News and Research

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Newsletters you may be interested in